RBC Capital analyst Arun Viswanathan maintained a Buy rating on Corteva (NYSE:CTVA) on Thursday, setting a price target of $52, which is approximately 6.43% above the present share price of $48.86.
Viswanathan expects Corteva to post earnings per share (EPS) of $0.81 for the second quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Corteva, with an average price target of $53.67.
The analysts price targets range from a high of $55 to a low of $52.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $4.18 billion and a net profit of $561 million. The company's market cap is $36.19 billion.
According to TipRanks.com, RBC Capital analyst Arun Viswanathan is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 13.1% and a 67.94% success rate.
Corteva, Inc. is an agricultural chemical and seed company. It develops and supplies advanced germplasm and traits that helps in maximizing yield for farms. It also supplies products that enhances enhance crop health and protectagainst weeds, insects and other pests, and diseases.